



LYPRINOL

Address: Calle Villajoyosa, 49 Polígono industrial La Alberca

Postal Code / District: 03530

Town: La Nucía **Province**: Alicante

Province: Alicante Country: ES
Phone: +34 96 689 76 22 Web: http://v

Foundation year: 1973

Web: http://www.lyprinol.es

The development of Lyprinol was in 1973 when the MacLab group became interested in growing mussels and tun extract from New Zealand green lipped mussel as a natural treatment for arthritis. In 1975 the MacLab group formed a joint venture to market a mussel extract of freeze-dried green mussel.

DESCRIPTION

The Pharmalink company has accumulated more than three decades of experience and research on New Zealand Perna Canaliculus, culminating in the development of Lyprinol®. This innovative breakthrough was led by the MacLab group, who not only invested in the company, but were also its partners.

The beginning of the development of Lyprinol® dates back to 1973, when the MacLab group became interested in mussel farming operations and proposed the idea of creating a New Zealand green lip mussel extract as a natural treatment for arthritis.

In 1975, they established a joint venture to market a powdered freeze-dried Perna Caniculus mussel extract, under the name "Seatone". This product was successful in Australia, New Zealand and later in the United Kingdom, despite opposition from some medical sectors.


Despite inconclusive early clinical studies, in 1980 Drs Sheila and Robert Gibson conducted a larger study that demonstrated the value of mussel extract in treating certain forms of arthritis, generating renewed interest in the product.

In 1982, the MacLab group acquired a mussel powder production factory in New Zealand and began a collaboration with the Royal Melbourne University Institute of Technology to research the properties of mussels.

In 1983, during a visit to Japan, a member of the MacLab group met Professor Takuo Kosuge, who offered the collaboration of his research group to study the mussel. Despite technical challenges, the mussel powder was eventually stabilized, allowing for more rigorous clinical research.

In 1997, a comparative study highlighted the difference between stabilized and unstable mussel powder in terms of beneficial activity. This led to the development of new extraction methods, such as the company's patented supercritical fluid extraction (SFE) process.









LYPRINOL

In 1992, Dr. Henry Betts joined the project and performed in vitro analyzes that confirmed the activity of certain fractions of the mussel. These results led to in vivo studies with laboratory animals, which corroborated the effectiveness of the product.

As a result of years of research, several international patents were obtained, including one on the stabilization of active lipids, the isolation of active fractions and the extraction process.

The greatest advance was the discovery of the competing fraction of pure Arachidonic Acid (AA), known as Lyprinol®. This led to the development of Lyprinol® Advanced, a synergistic combination of mussel and krill extracts that offers a new clinical option for treating inflammatory conditions.

PRODUCTS:



LYPRINOL ADVANCE 60 Pearls

PVP 37,75€

